Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir/lamivudine vs current cART in virologically suppressed adults with HIV-1
CTR20191879Phase 3Active
- Sponsor
- GSK
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV), sponsored by GSK. Started Dec 2019; status: active.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20191879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191879.